Literature DB >> 9371608

Increased probability of expression from modified retroviral vectors in embryonal stem cells and embryonal carcinoma cells.

P B Robbins1, X J Yu, D M Skelton, K A Pepper, R M Wasserman, L Zhu, D B Kohn.   

Abstract

Gene expression from the Moloney murine leukemia retrovirus (Mo-MuLV) is highly restricted in embryonic carcinoma (EC) and embryonic stem (ES) cells. We compared levels of expression in PA317 fibroblasts, F9 (EC) cells, and CCE (ES) cells by Mo-MuLV-based vectors and vectors based on our previously reported MND backbone, which has alterations to address three viral elements implicated as repressors of expression by Mo-MuLV: the enhancer, the primer binding site, and the negative-control region. Expression was evaluated with three reporter genes, the chloramphenicol acetyltransferase (CAT) gene, whose expression was measured by enzymatic assay and by Northern blotting; a truncated nerve growth factor receptor (tNGFR), whose expression was measured by fluorescence-activated cell sorting (FACS) as a cell surface protein; and the enhanced green fluorescent protein (EGFP), whose expression was measured intracellularly by flow cytometry. We found significantly higher levels of CAT activity (5- to 300-fold) and greater quantities of vector-specific transcripts in ES and EC cells transduced with the modified MND-CAT-SN vector than in those transduced with L-CAT-SN. Northern blot analysis indicated that long terminal repeat transcripts from MND-CAT-SN are >80 times more abundant than the L-CAT-SN transcripts. FACS analysis of tNGFR expression from a pair of vectors, L-tNGFR-SN and MND-tNGFR-SN, indicated that only 1.04% of the CCE cells containing the L-tNGFR-SN vector expressed the cell surface reporter, while the MND-tNGFR-SN vector drove expression in 99.54% of the CCE cells. Of the F9 cells containing the L-tNGFR-SN vector, 13.32% expressed tNGFR, while 99.89% of the F9 cells transduced with MND-tNGFR-SN showed expression. Essentially identical results were produced with an analogous pair of vectors encoding EGFP. In unselected pools of F9 cells 48 h posttransduction, the L-EGFP-SN vector drove expression in only 5% of the population while the MND-EGFP-SN vector drove expression in 88% of the cells. After more than 3 weeks in culture without selection, the proportion of cells showing expression from L-EGFP-SN decreased slightly to 3% while expression from the MND-EGFP-SN vector persisted in 80% of the cells. Interestingly, in the few ES and EC cells which did show expression from the L-tNGFR-SN or L-EGFP-SN vectors, the magnitude of reporter expression was similar to that from the MND-tNGFR-SN or MND-EGFP-SN vector in nearly all cells, suggesting that the MND vectors are far less susceptible to position-dependent variegation of expression than are the Mo-MuLV-based vectors. Therefore, the modified retroviral vector, MND, achieves higher net levels of expression due to a greater frequency of expression, which may be useful for the expression of exogenous genes in EC and ES cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9371608      PMCID: PMC230252     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Analysis of the relative level of gene expression from different retroviral vectors used for gene therapy.

Authors:  J Byun; S H Kim; J M Kim; S S Yu; P D Robbins; J Yim; S Kim
Journal:  Gene Ther       Date:  1996-09       Impact factor: 5.250

2.  Functional analysis of a retroviral host-range mutant: altered long terminal repeat sequences allow expression in embryonal carcinoma cells.

Authors:  F Hilberg; C Stocking; W Ostertag; M Grez
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

3.  Negative regulation of viral enhancers in undifferentiated embryonic stem cells.

Authors:  C M Gorman; P W Rigby; D P Lane
Journal:  Cell       Date:  1985-09       Impact factor: 41.582

4.  Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production.

Authors:  A D Miller; C Buttimore
Journal:  Mol Cell Biol       Date:  1986-08       Impact factor: 4.272

Review 5.  The current status of gene therapy using hematopoietic stem cells.

Authors:  D B Kohn
Journal:  Curr Opin Pediatr       Date:  1995-02       Impact factor: 2.856

6.  Independent mechanisms involved in suppression of the Moloney leukemia virus genome during differentiation of murine teratocarcinoma cells.

Authors:  O Niwa; Y Yokota; H Ishida; T Sugahara
Journal:  Cell       Date:  1983-04       Impact factor: 41.582

7.  DNA methylation and genetic instability in colorectal cancer cells.

Authors:  C Lengauer; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

8.  Sp1 elements protect a CpG island from de novo methylation.

Authors:  M Brandeis; D Frank; I Keshet; Z Siegfried; M Mendelsohn; A Nemes; V Temper; A Razin; H Cedar
Journal:  Nature       Date:  1994-09-29       Impact factor: 49.962

9.  Deletions in a recombinant retrovirus genome associated with its expression in embryonal carcinoma cells.

Authors:  M Taketo; D J Shaffer
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

10.  Cloning of a negative transcription factor that binds to the upstream conserved region of Moloney murine leukemia virus.

Authors:  J R Flanagan; K G Becker; D L Ennist; S L Gleason; P H Driggers; B Z Levi; E Appella; K Ozato
Journal:  Mol Cell Biol       Date:  1992-01       Impact factor: 4.272

View more
  25 in total

1.  DNA methylation of helper virus increases genetic instability of retroviral vector producer cells.

Authors:  W B Young; G L Lindberg; C J Link
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites.

Authors:  S Rivella; J A Callegari; C May; C W Tan; M Sadelain
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors.

Authors:  S S Case; M A Price; C T Jordan; X J Yu; L Wang; G Bauer; D L Haas; D Xu; R Stripecke; L Naldini; D B Kohn; G M Crooks
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

4.  Lack of shielding of primer binding site silencer-mediated repression of an internal promoter in a retrovirus vector by the putative insulators scs, BEAD-1, and HS4.

Authors:  C Modin; F S Pedersen; M Duch
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 5.  Hematopoietic stem cell gene therapy.

Authors:  David W Emery; Tamon Nishino; Ken Murata; Michalis Fragkos; George Stamatoyannopoulos
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

6.  MYC and PIM2 co-expression in mouse bone marrow cells readily establishes permanent myeloid cell lines that can induce lethal myeloid sarcoma in vivo.

Authors:  Su Hwa Jang; Hee Yong Chung
Journal:  Mol Cells       Date:  2012-07-26       Impact factor: 5.034

7.  Consistent, persistent expression from modified retroviral vectors in murine hematopoietic stem cells.

Authors:  P B Robbins; D C Skelton; X J Yu; S Halene; E H Leonard; D B Kohn
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

8.  Tissue inhibitor of metalloproteinase-3 (TIMP-3) regulates hematopoiesis and bone formation in vivo.

Authors:  Yi Shen; Ingrid G Winkler; Valerie Barbier; Natalie A Sims; Jean Hendy; Jean-Pierre Lévesque
Journal:  PLoS One       Date:  2010-09-30       Impact factor: 3.240

9.  The Moloney murine leukemia virus repressor binding site represses expression in murine and human hematopoietic stem cells.

Authors:  Dennis L Haas; Carolyn Lutzko; Aaron C Logan; Gerald J Cho; Dianne Skelton; Xiao Jin Yu; Karen A Pepper; Donald B Kohn
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  Serial bone marrow transplantation reveals in vivo expression of the pCLPG retroviral vector.

Authors:  Paula Fratini; Bryan E Strauss
Journal:  Virol J       Date:  2010-01-22       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.